Mosunetuzumab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 134 publications
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.
Journal: International journal of clinical oncology
Published: April 09, 2026
T-cell engagers in rheumatology.
Journal: Best practice & research. Clinical rheumatology
Published: January 30, 2026
Bispecific Antibodies in B-Cell Lymphomas: Mechanisms, Efficacy, Toxicity, and Management.
Journal: Medicina (Kaunas, Lithuania)
Published: January 06, 2026
Advances in the clinical application of bispecific antibodies in cancer therapy.
Journal: iScience
Published: January 01, 2026
Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: December 24, 2025
Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomas.
Journal: Expert opinion on biological therapy
Published: December 12, 2025
CD20 Loss as a Mechanism of Resistance to Mosunetuzumab in Relapsed Follicular Lymphoma.
Journal: Mediterranean journal of hematology and infectious diseases
Published: November 29, 2025
Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
Journal: American journal of hematology
Published: November 21, 2025
Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphoma.
Journal: International journal of clinical oncology
Published: October 29, 2025
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 02, 2025
T-cell engaging antibodies for B-cell lymphomas.
Journal: Seminars in hematology
Published: September 21, 2025
Sequencing Cellular Therapies in the Management of Follicular Lymphoma.
Journal: Cells
Published: September 08, 2025
Last Updated: 04/28/2026